Robert Rissmann
Bijzonder hoogleraar Translationele Dermatologie
- Naam
- Prof.dr. R. Rissmann
- Telefoon
- +31 71 527 2727
- r.rissmann@lacdr.leidenuniv.nl
Nieuws
-
Huidonderzoeker pleit voor multidisciplinaire samenwerking: ‘Ik wil expertise bundelen.' -
Huidziekten beter behandelen dankzij NWA-subsidie van 11,7 miljoen euro -
Psychologen betrokken bij hightech biomarkeronderzoek in de gezondheidszorg -
NWA-subsidie voor meerdere interdisciplinaire consortia
-
Robert Rissmann nieuwe hoogleraar Translationele dermatologie bij LACDR-CHDR -
Miljoenen mensen te helpen met nieuwe synthetische huidcrème
Bijzonder hoogleraar Translationele Dermatologie
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Drug Delivery Technology
- Rousel J., Bergmans M.E., Meulen L.W.J. van der, Pagan L., Bruin D.T. de, Kam M.L. de, Klarenbeek N.B., Bouwstra J.A., Seyger M.M.B., Reek J.M.P.A. van den, Niemeyer-van der Kolk T., Rissmann R., Doorn M.B.A. van & NGID consortium (2024), Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trial, Journal of The American Academy of Dermatology 90(2): 395-397.
- Wu S., Huisman B.W., Rietveld M.H., Rissmann R., Vermeer M.H., Poelgeest M.I.E. van & El Ghalbzouri A. (2024), The development of in vitro organotypic 3D vulvar models to study tumor-stroma interaction and drug efficacy, Cellular Oncology : .
- Bekkers V.Z., Khan F., Aarts P., Zdunczyk K., Prens E.P., Wolkerstorfer A., Rissmann R. & Doorn M.B.A. van (2024), Needle-free electronically-controlled jet injector treatment with bleomycin and lidocaine is effective and well-tolerated in patients with recalcitrant keloids, Lasers in Surgery and Medicine 56(1): 45-53.
- Rousel J., Saghari M., Pagan L., Nadaban A., Gambrah T., Theelen B., Kam M.L. de, Haakman J., Wall H.E.C. van der, Feiss G.L., Niemeyer-van der Kolk T., Burggraaf J., Bouwstra J.A., Rissmann R. & Doorn M.B.A. van (2023), Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial, International Journal of Molecular Sciences 24(18): 14315.
- Voorde W. ten: Saghari M., Boltjes J., Kam M.L. de, Zhuparris A., Feiss G., Buters T.P., Prens E.P., Damman J., Niemeyer-van der Kolk T., Moerland M., Burggraaf J., Doorn M.B.A. van & Rissmann R. (2023), A multimodal, comprehensive characterization of a cutaneous wound model in healthy volunteers, Experimental Dermatology 32(7): 1028-1041.
- Nadaban A., Rousel J., El Yachioui D., Gooris G.S., Beddoes C.M., Dalgliesh R.M., Malfois M., Rissmann R. & Bouwstra J.A. (2023), Effect of sphingosine and phytosphingosine ceramide ratio on lipid arrangement and barrier function in skin lipid models, Journal of Lipid Research 64(8): 100400.
- Rousel J., Nadaban A., Saghari M., Pagan L., Zhuparris A., Theelen B., Gambrah T., Wall H.E.C. van der, Vreeken R.J., Feiss G.L., Niemeyer-van der Kolk T., Burggraaf J. Doorn M.B.A. van, Bouwstra J.A. & Rissmann R. (2023), Lesional skin of seborrheic dermatitis patients is characterized by skin barrier dysfunction and correlating alterations in the stratum corneum ceramide composition, Experimental Dermatology 33(1): 14952.
- Kraaij S.J.W. van, Hamblin M.R., Pickering G., Giannokopoulos B., Kechemir H., Heinz M., Igracki-Turudic I., Yavuz Y., Rissmann R. & Gal P. (2023), A Phase 1 randomized, open-label clinical trial to evaluate the effect of a far-infrared emitting patch on local skin perfusion, microcirculation and oxygenation, Experimental Dermatology 33(1): e14962.
- Huisman B.W., Nené L.E.H., Linders F.L.L., Gambrah T.K., Kolk T.N. van der, Kam M.L. de, Bavinck J.N.B., Burggraaf J., Feiss G. & Rissmann R. (2023), No effect of topical digoxin and furosemide for patients with actinic keratosis, Journal of the European Academy of Dermatology and Venereology 37(2): e172-e174.
- Pagan L., Huisman B.W., Wurff M. van der, Naafs R.G.C., Schuren F.H.J., Sanders I.M.J.G., Smits W.K., Zwittink R.D., Burggraaf J., Rissmann R., Piek J.M.J., Henderickx J.G.E. & Poelgeest M.I.E. van (2023), The vulvar microbiome in lichen sclerosus and high-grade intraepithelial lesions, Frontiers in Microbiology 14: 1264768.
- Huisman B.W., Pagan L., Naafs R.G.C., Voorde W. ten, Rissmann R., Piek J.M.J., Damman J., Juachon M.J., Osse M., Niemeyer-van der Kolk T., Hees C.L.M. van & Poelgeest M.I.E. van (2023), Dermatoscopy and optical coherence tomography in vulvar high-grade squamous intraepithelial lesions and lichen sclerosus: a prospective observational trial, Journal of Lower Genital Tract Disease 27(3): 255-261.
- Voorde W. ten, Akinseye C., Abdisalaam I., Wind S., Klarenbeek N., Bergmans M., Doorn M. van, Rissmann R., Kaur R., Hotee S., Foster K., Nair A., Fortunato L., Macphee C., Mole S., Baumann K. & Brigandi R. (2023), Intradermal substance P as a challenge agent in healthy individuals, Journal of Clinical and Translational Science 16(10): 1856-1865.
- Assil S., Buters T.P., Hameeteman P.W., Hallard C., Treijtel N., Niemeyer-Van der Kolk T., Kam M.L. de, Florencia E.F.I.I.I., Prens E.P., Doorn M.B.A. van, Rissmann R., Klarenbeek N.B., Jansen M.A.A. & Moerland M. (2023), Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model, Frontiers in Immunology 14: 1197650.
- Huisman B.W., Pagan L., Ulrich M., Rissmann R., Damman J., Piek J.M.J., Niemeyer-van der Kolk T. & Poelgeest M.I.E. van (2023), Reflectance confocal microscopy as a non-invasive imaging tool in vulvar high-grade squamous intraepithelial lesions and lichen sclerosus: a descriptive morphological study in patients and healthy volunteers, Experimental Dermatology 32(10): 1734-1743.
- Jong L.M. de, Boussallami S., Sánchez-López E., Giera M., Tushuizen M.E., Hoekstra M., Hawinkels L.J.A.C., Rissmann R., Swen J.J. & Manson M.L. (2023), The impact of CYP2C19 genotype on phenoconversion by concomitant medication, Frontiers in Pharmacology 14: 1201906.
- Wall H.E.C. van der Doll R.J., Westen G.J.P. van, Niemeyer-van der Kolk T., Feiss G., Pinckaers H., Doorn M.B.A. van, Nijsten T., Sanders M.G.H., Cohen A.F., Burggraaf J., Rissmann R. & Pardo L.M. (2022), Discriminative machine learning analysis for skin microbiome: observing biomarkers in patients with seborrheic dermatitis, Journal of Artificial Intelligence for Medical Sciences 3(1-2): 1-7.
- Ligt R. de, Westerhout J., Grossouw D., Buters T.P., Rissmann R., Burggraaf J., Windhorst A.D., Tozer S., Pappa G., Wall B., Bury D., Mason D.R. & Vaes W.H.J. (2022), Assessment of dermal absorption of aluminium from a representative antiperspirant formulation using a (Al-26)Al microtracer approach: a follow-up study in humans, Toxicology Research 11(3): 511-519.
- Thibouto D.M., Craft N., Rissmann R., Gatlik E., Souquières M., Jones J. & Loesche C. (2022), Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne, Journal of Dermatological Treatment : 2138691 .
- Wind S.S., Jansen M.A.A., Rijsbergen M., Esdonk M.J. van, Ziagkos D., Cheng W.C., Kolk-Niemeyer T. van der, Korsten J., Gruszka A., Schmitz-Rohmer D., Bonnel D., Legouffe R., Barré F., Bekkenk M.W., Haas E.R.M. de, Quint K.D., Rolli M., Streefkerk H.J., Burggraaf J., Vermeer M.H. & Rissmann R. (2022), Topical bimiralisib shows meaningful cutaneous drug levels in healthy volunteers and mycosis fungoides patients but no clinical activity in a first-in-human, randomized controlled trial, Cancers 14(6): 1510.
- Jong L.M. de, Klomp S.D., Treijtel N., Rissmann R., Swen J.J. & Manson M.L. (2022), A systematic review on disease-drug-drug interactions with immunomodulating drugs: a critical appraisal of risk assessment and drug labelling, British Journal of Clinical Pharmacology 88(10): 4387-4402.
- Balak D.M.W. & Rissmann R. (2022), Commentary: anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave, British Journal of Dermatology 187(5): 633-634.
- Buters T.P., Hameeteman P., Jansen I..H.M., Hindevoort F.C. van, Voorde W. ten., Grievink H.W., Schoonakker M., Kam M.L. de, Gilroy D.W., Feiss G., Rissmann R., Jansen M.A.A., Burggraaf J. & Moerland M. (2022), Clinical, cellular, and molecular effects of Corticosteroids on the response to Intradermal Lipopolysaccharide administration in healthy volunteers, Clinical Pharmacology & Therapeutics 111(4): 964-971.
- Radanovic I., Klarenbeek N., Rissmann R., Groeneveld G.J., Brummelen E.M.J. van, Moerland M. & Bosch J.J. (2022), Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds, Frontiers in Oncology 12: 954806.
- Pagan L., Yfanti C., Rijneveld R., Todd M., Jongste P., Feijen J.J., Klaassen E.S., Bouwes Bavinck J.N., Struijk L., Koning M.N.C. de, Prestegarden L., Niemeyer-van der Kolk T., Poelgeest M.I.E. & Rissmann R. (2022), Results of a randomized, placebo-controlled, first-in-human trial of topical CY-002 in patients with cutaneous warts, Journal of the European Academy of Dermatology and Venereology 36(10): e773-e775.
- Saghari M., Gal P., Gilbert S., Yateman M., Porter-Brown B., Brennan N., Quaratino S., Wilson R., Grievink H.W., Klaassen E.S., Bergmann K.R., Burggraaf J., Doorn M.B.A. van, Powell J., Moerland M. & Rissmann R. (2022), OX40L Inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005, Clinical Pharmacology & Therapeutics 111(5): 1121-1132.
- Buters T.P., Hameeteman P.W., Jansen I.M.E., Hindevoort F.C. van, Voorde W. ten, Florencia E., Osse M., Kam M.L. de, Grievink H.W., Schoonakker M., Patel A.A., Yona S., Gilroy D.W., Lubberts E., Damman J., Feiss G., Rissmann R., Jansen M.A.A., Burggraaf J. & Moerland M. (2022), Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers, British Journal of Clinical Pharmacology 88(2): 680-690.
- Jacobse J., Voorde W. ten, Tandon A., Romeijn S.G., Grievink H.W., Maaden K. van der, Esdonk M.J. van, Moes D.J.A.R., Loeff F., Bloem K., Vries A. de, Rispens T., Wolbink G., Kam M. de, Ziagkos D., Moerland M., Jiskoot W., Bouwstra J., Burggraaf J., Schrier L., Rissmann R. & Cate R. ten (2021), Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial, British Journal of Clinical Pharmacology 87(8): 3162-3176.
- Saghari M., Gal P., Ziagkos D., Burggraaf J., Powell J.F., Brennan N., Rissmann R., Doorn M.B.A. van & Moerland M. (2021), A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man, British Journal of Clinical Pharmacology 87(4): 1953-1962.
- Pagan L., Ederveen R.A.M., Huisman B.W., Schoones J.W., Zwittink R.D., Schuren F.H.J., Rissmann R., Piek J.M.J. & Poelgeest M.I.E. van (2021), The human vulvar microbiome: a systematic review, Microorganisms 9(12): 2568.
- Huisman B.W., Cankat M., Bosse T., Vahrmeijer A.L., Rissmann R., Burggraaf J., Sier C.F.M. & Poelgeest M.I.E. van (2021), Integrin αvβ6 as a target for tumor-specific imaging of vulvar squamous cell carcinoma and adjacent premalignant lesions, Cancers 13(23): 6006.
- Rissmann R. & Zuiker R. (2021), Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et al, British Journal of Clinical Pharmacology 87(7): 2633-2634.
- Rissmann R., Moerland M. & Doorn M.B.A. van (2020), Blueprint for mechanistic, data-rich early phase clinical pharmacology studies in dermatology, British Journal of Clinical Pharmacology 86(6): 1011-1014.
- Rijsbergen M., Rijneveld R., Todd M., Feiss G.L., Kouwenhoven S.T.P., Quint K.D., Alewijk D.C.J.G. van, Koning M.N.C. de, Klaassen E.S., Burggraaf J., Rissmann R. & Poelgeest M.I.E. van (2020), Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions, British Journal of Clinical Pharmacology 86(11): 2133-2143.
- Niemeyer-van der Kolk T., Wall H. van der, Hogendoorn G.K., Rijneveld R., Luijten S., Alewijk D.C.J.G. van, Munckhof E.H.A. van den, Kam M.L. de, Feiss G.L., Prens E.P., Burggraaf J., Rissmann R. & Doorn M.B.A. van (2020), Pharmacodynamic effects of topical Omiganan in patients with mild to moderate atopic dermatitis in a randomized, placebo-controlled, phase II trial, CTS-Clinical and Translational Science 13(5): 994-1003.
- Huisman B.W., Burggraaf J., Vahrmeijer A.L., Schoones J.W., Rissmann R., Sier C.F.M. & Poelgeest M.I.E. van (2020), Potential targets for tumor-specific imaging of vulvar squamous cell carcinoma: a systematic review of candidate biomarkers, Gynecologic Oncology 156(3): 734-743.
- Niemeyer-van der Kolk T., Assil S., Buters T.P., Rijsbergen M., Klaassen E.S., Feiss G., Florencia E., Prens E.P., Burggraaf J., Doorn M.B.A. van, Rissmann R. & Moerland M. (2020), Omiganan enhances imiquimod-induced inflammatory responses in skin of healthy volunteers, Clinical and Translational Science 13(3): 573-579.
- Rijsbergen M., Niemeyer-van der Kolk T., Rijneveld R., Pinckaers J.H.F.M., Meshcheriakov I., Bavinck J.N.B., Doorn M.B.A. van, Hogendoorn G., Feiss G., Cohen A.F., Burggraaf J., Poelgeest M.I.E. van & Rissmann R. (2020), Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology, Journal of the European Academy of Dermatology and Venereology 34(3): 633-639.
- Munckhof E.H.A. van den, Niemeyer-Van der Kolk T., Wall H.E.C. van der, Alewijk D.C.J.G. van, Doorn M.B.A. van, Burggraaf J., Buters T.P., Becker M.J., Feiss G.L., Quint W.G.V., Doorn L.J. van, Knetsch C.W. & Rissmann R. (2020), Inter- and intra-patient variability over time of lesional skin microbiota in adult patients with atopic dermatitis, Acta Dermato-Venereologica 100(1): adv00018.
- Kolk T.N. van der, Buters T.P., Krouwels L., Boltjes J., Kam M.L. de, Wall H. van der, Alewijk D.C.J.G. van, Munckhof E.H.A. van den, Becker M.J., Feiss G., Florencia E.F., Prens E.P., Moerland M., Burggraaf J., Rissmann R. & Doorn M.B.A. van (2020), Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial, Journal of The American Academy of Dermatology 86(4): 854-862.
- Grievink H.W., Jirka S.M.G., Woutman T.D., Schoonakker M., Rissmann R., Malone K.E., Feiss G. & Moerland M. (2020), Antimicrobial peptide omiganan enhances interferon responses to endosomal toll-like receptor ligands in human peripheral blood mononuclear cells, Clinical and Translational Science 13(5): 891-895.
- Rijsbergen M., Rijneveld R., Todd M., Pagan L., Feiss G., Koning M.N.C. de, Alewijk D.C.J.G. van, Klaassen E.S., Burggraaf J., Rissmann R. & Poelgeest M.I.E. van (2020), No effect of topical digoxin and furosemide gel for patients with external anogenital warts, Journal of the European Academy of Dermatology and Venereology 34(1): E45-E46.
- Rijsbergen M., Niemeyer-van der Kolk T., Hogendoorn G., Kouwenhoven S., Lemoine C., Klaassen E.S., Koning M. de, Beck S., Bavinck J.N.B., Feiss G., Burggraaf J. & Rissmann R. (2019), A randomized controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts, British Journal of Dermatology 180(5): 1058-1068.
- Ruiter R., Burggraaf J. & Rissmann R. (2019), Under-representation of elderly in clinical trials: an analysis of the initial approval documents in the Food and Drug Administration database, British Journal of Clinical Pharmacology 85(4): 838-844.
- Jansen D.R.M., Keijsers C.J.P.W., Kornelissen M.O., Rikkert M.G.M.O., Kramers C., Tichelaar J., Janssen B., Brink A.M. van den, Peeters L., Dumont G., Hessel M., Rissmann R. & Knol W. (2019), Towards a "prescribing license" for medical students: development and quality evaluation of an assessment for safe prescribing, European Journal of Clinical Pharmacology 75(9): 1261-1268.
- Rijsbergen M., Pagan L., Niemeyer-van der Kolk T., Rijneveld R., Hogendoorn G., Lemoine C., Miranda Y.M., Feiss G., Bavink J.N.B., Burggraaf J., Poelgeest M.I.E. van & Rissmann R. (2019), Stereophotogrammetric three-dimensional photography is an accurate and precise planimetric method for the clinical visualization and quantification of human papilloma virus-induced skin lesions, Journal of the European Academy of Dermatology and Venereology 33(8): 1506-1512.
- Rissmann R. & Szabadi E. (2019), Spotlight commentary: how to prove pharmacology of immunomodulatory drugs in a phase 1 trial?, British Journal of Clinical Pharmacology 85(7): 1389-1390.
- Jacobse J., Voorde W. ten, Rissmann R., Burggraaf J., Cate R. ten & Schrier L. (2019), The effect of repeated methotrexate injections on the quality of life of children with rheumatic diseases, European Journal of Pediatrics 178(1): 17-20.
- Siebenga P.S., Amerongen G. van, Klaassen E.S., Kam M.L. de, Rissmann R. & Groeneveld G.J. (2019), The ultraviolet B inflammation model: postinflammatory hyperpigmentation and validation of a reduced UVB exposure paradigm for inducing hyperalgesia in healthy subjects, European Journal of Pain 23(5): 874-883.
- Niemeyer-van der Kolk T., Wall H.E.C. van der, Balmforth C., Doorn M.B.A. van & Rissmann R. (2018), A systematic literature review of the human skin microbiome as biomarker for dermatological drug development, British Journal of Clinical Pharmacology 84(10): 2178-2193.
- Hogendoorn G.K., Bruggink S.C., Koning M.N.C. de, Eekhof J.A.H., Hermans K.E., Rissmann R., Burggraaf J., Wolterbeek R., Quint K.D., Kouwenhoven S.T.P. & Bavinck J.N.B. (2018), Morphological characteristics and human papillomavirus genotype predict the treatment response in cutaneous warts, British Journal of Dermatology 178(1): 253-260.
- Labots G., Jones A., Visser S.J. de, Rissmann R. & Burggraaf J. (2018), Gender differences in clinical registration trials: is there a real problem?, British Journal of Clinical Pharmacology 84(4): 700-707.
- Kolk T. van der, Assil S., Rijneveld R., Klaassen E.S., Feiss G., Florencia E., Prens E.P., Burggraaf J., Moerland M., Rissmann R. & Doorn M.B.A. van (2018), Comprehensive, multimodal characterization of an imiquimod-induced human skin inflammation model for drug development, Clinical and Translational Science 11(6): 607-615.
- Hogendoorn G.K., Bruggink S.C., Hermans K.E., Kouwenhoven S.T.P., Quint K.D., Wolterbeek R., Eekhof J.A.H., Koning M.N.C. de, Rissmann R., Burggraaf J. & Bavinck J.N.B. (2018), Developing and validating the Cutaneous WARTS (CWARTS) diagnostic tool: a novel clinical assessment and classification system for cutaneous warts, British Journal of Dermatology 178(2): 527-534.
- Jansen B.H.E., Disselhorst G.W., Schutte T., Jansen B., Rissmann R., Richir M.C., Keijsers C.J.P.W., Vanmolkot F.H.M., Brink A.M. van den, Kramers C., Vondeling A.M., Dumont G.J.H., Waard-Siebinga I. de, Agtmael M.A. van & Tichelaar J. (2018), Essential diseases in prescribing: a national Delphi study towards a core curriculum in pharmacotherapy educatio, British Journal of Clinical Pharmacology 84(11): 2645-2650.
- Kolk T. van der & Rissmann R. (2018), Reply to 'Topical ionic contra-viral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts', Journal of the European Academy of Dermatology and Venereology 32(4): E156-E156.
- Giang J., Seelen M.A.J., Doorn M.B.A. van, Rissmann R., Prens E.P. & Damman J. (2018), Complement activation in inflammatory skin diseases, Frontiers in immunology 9: 639.
- Balak D.M.W., Doorn M.B.A. van, Arbeit R.D., Rijneveld R., Klaassen E., Sullivan T., Brevard J., Thio H.B., Prens E.P., Burggraaf J. & Rissmann R. (2017), IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis, Clinical Immunology 174: 63-72.
- Meer L. van, Moerland M., Gallagher J., Doorn M.B.A. van, Prens E.P., Cohen A.F., Rissmann R. & Burggraaf J. (2017), Injection site reactions after subcutaneous oligonucleotide therapy, British Journal of Clinical Pharmacology 82(2): 340-351.
- Schutte T., Tichelaar J., Reumerman M.O., Eekeren R. van, Rissmann R., Kramers C., Richir M.C., Puijenbroek E.P. van & Agtmael M.A. van (2017), Pharmacovigilance skills, knowledge and attitudes in our future doctors : a nationwide study in the Netherlands, Basic & Clinical Pharmacology & Toxicology 120(5): 475-481.
- Kolk T. van der, Dillingh M.R., Rijneveld R., Klaassen E.S., Koning M.N.C. de, Kouwenhoven S.T.P., Genders R.E., Bavinck J.N.B., Feiss G., Rissmann R. & Burggraaf J. (2017), Topical ionic contra-viral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts, Journal of the European Academy of Dermatology and Venereology 31(12): 2088-2090.
- Goulooze S.C., Franson K.L., Cohen A.F. & Rissmann R. (2017), Clinical Pharmacology Research Internships at the Interface between Academia and Industry: Students' Perceptions and Scientific Output, Basic & Clinical Pharmacology & Toxicology 121(1): 22-28.
- Baakman A.C., Alvarez-Jimenez R., Rissmann R., Klaassen E.S., Stevens J., Goulooze S.C., Burger J.C.G. den, Swart E.L., Gerven J.M.A. van & Groeneveld G.J. (2017), An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine, British Journal of Clinical Pharmacology 83(8): 1676-1687.
- Alvarez Jimenez R., Baakman A.C., Stevens J., Goulooze S.C., Hart E.P., Rissmann R., Gerven J.M.A. van & Groeneveld G.J. (2017), Pharmacokinetics and pharmacodynamics of oral mecamylamine – development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation, Journal of Psychopharmacology 31(2): 192-203.
- Goulooze S.C., Cohen A.F. & Rissmann R. (2016), Olaparib, British Journal of Clinical Pharmacology 81(1): 171-173.
- Goulooze S.C., Cohen A.F. & Rissmann R. (2015), Bedaquiline, British Journal of Clinical Pharmacology 80(2): 182-184.
- Goulooze S.C., Cohen A.F. & Rissmann R. (2015), Mirabegron, British Journal of Clinical Pharmacology 80(4): 762-764.
- Goulooze S.C., Cohen A.F. & Rissmann R. (2015), Lomitapide, British Journal of Clinical Pharmacology 80(2): 179-181.
- Smeden J. van, Boiten W.A., Hankemeier T., Rissmann R., Bouwstra J.A. & Vreeken R.J. (2014), Combined LC/MS-platform for analysis of all major stratum corneum lipids, and the profiling of skin substitutes, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 1841(1): 70-79.
- Scientist
- Research Director Dermatology